retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, the triple-G (GLP-1, GIP, and receptor) caused patients with and knee osteoarthritis to lose an average of 23.7% of body weight after 68 weeks, according to the results Dual and Triple Gut Peptide

Those few minutes of stillness might be the calmest part of your day

The goal should be to preserve those benefits while reducing avoidable losses in strength, function, and nutritional status

Hair thinning has been noted in association with retatrutide, likely related to rapid weight loss triggering telogen effluvium, though a direct pharmacological effect cannot be excluded as alopecia is listed as an adverse reaction with some licensed GLP-1 receptor agonists

In vitro and preclinical studies highlight the complexity of GLP-1 signaling in cancer biology

Patients should monitor their symptom patterns and discuss timing adjustments with their healthcare provider if side effects are limiting treatment adherence